LAVA THERAPEUTICS B V has a total of 20 patent applications. Its first patent ever was published in 2015. It filed its patents most often in Australia, Canada and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are AFFIMED THERAPEUTICS AG, AGOMAB THERAPEUTICS BVBA and QUADRUCEPT BIO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 4 | |
#2 | Canada | 3 | |
#3 | United States | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Singapore | 2 | |
#7 | Hong Kong | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Van Der Vliet Johannes Jelle | 18 |
#2 | De Gruijl Tanja Denise | 15 |
#3 | Verheul Hendrik Marinus Willem | 11 |
#4 | Lameris Roeland | 7 |
#5 | Parren Paul Willem Henri Ida | 7 |
#6 | Lameris Roland | 6 |
#7 | De Bruin Renée Cornelia Gerarda | 6 |
#8 | De Bruin Renee Cornelia Gerarda | 5 |
#9 | Riedl Thilo Alexander | 2 |
#10 | De Weerdt Iris | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020060405A1 | Dual acting cd1d immunoglobulin | |
EP3792283A1 | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies | |
AU2015244489A1 | Immunoglobulins binding human Vgamma9Vdelta2 T cell receptors |